CHM.CN (Waverunner Capital CNQ) at C$0.05 14 Mar 2026: high-volume signals to watch

The CHM.CN stock surged to C$0.05 on CNQ on 14 Mar 2026, marking a 900.00% one-day change from the prior close and drawing high-volume attention in Canada market hours. This rapid move followed a string of news and a corporate rebrand to Waverunner Capital Inc., and it pushed the market cap to roughly C$37,211,650.00. Traders should focus on liquidity, average volume of 28,908 shares, and the gap between the 50-day average C$0.04 and the current price for short-term trading signals.

CHM.CN stock price and intraday volume signals

CHM.CN stock closed at C$0.05 after a one-day gain of 900.00%, driven by a sharp gap from the previous close of C$0.005. Volume data is patchy intraday, but the stock’s 50-day average price C$0.04 and average volume 28,908 show the move outpaced typical liquidity.

One clear trading claim: this is a high-volume mover scenario where rapid price spikes can create short-term volatility and wide bid-ask spreads. Active traders should size positions carefully and watch real-time quotes on CNQ for execution risk.

CHM.CN stock fundamentals and valuation metrics

Waverunner Capital Inc. (CHM.CN) reports EPS C$-0.01 and a negative PE at -5.00, reflecting recent losses and small reported earnings. The shares-outstanding count is 744,233,000 and market cap is roughly C$37,211,650.00, underlining microcap status with limited free float.

Balance-sheet metrics highlight risk: current ratio 0.10, cash per share C$0.01, and book value per share C$-0.14. One claim: valuation measures point to speculative status, not fundamental stability for income or value investors.

Meyka AI technical grade and CHM.CN stock rating

Meyka AI rates CHM.CN with a score out of 100: 65.00, Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

This rating indicates a cautious stance: the model sees modest structural upside but flags liquidity and profitability weaknesses. Grades are informational only and not investment advice.

CHM.CN stock sector context and comparable trends

Waverunner Capital sits in the Healthcare sector under Drug Manufacturers – Specialty & Generic, a sector that has shown mixed returns YTD. The healthcare sector average metrics show pressure on small-cap names and tighter trading ranges, increasing relative volatility for CHM.CN stock.

Investors should compare CHM.CN to small-cap healthcare peers on metrics like price/book and current ratio. One claim: sector headwinds amplify company-level liquidity and operational risks for microcaps.

Catalysts, risks and recent corporate updates for CHM.CN stock

Key catalysts include Waverunner’s June 2024 name change from Chemistree Technology and ongoing VC-style investments in renewables and biotech ventures. Those strategic shifts can re-rate sentiment if asset realizations occur.

The main risk claim: limited operating cash, negative free cash flow per share C$-0.03, and very low current ratio increase dilution and financing risk. Watch press releases and filings for PIPEs, recapitalizations, or equity raises.

Trading strategy and liquidity considerations for CHM.CN stock

For high-volume mover strategies, set firm entry and exit levels and use limit orders given likely wide spreads at C$0.05. Average volume 28,908 suggests trades above small sizes will move the market.

One tactical claim: short-term traders can use the 50-day average C$0.0424 and 200-day average C$0.0481 as reference points, but position sizing must account for high volatility and execution slippage on CNQ.

Final Thoughts

Key takeaways: CHM.CN stock is a microcap, high-volume mover trading at C$0.05 on CNQ on 14 Mar 2026 with a one-day change of 900.00% and market cap about C$37,211,650.00. Fundamentals show EPS C$-0.01, negative PE, low current ratio 0.10, and negative book value per share, which together imply elevated financing and dilution risk. Traders attracted to momentum should respect liquidity limits and real-time spreads. Meyka AI’s forecast model projects a 12-month target of C$0.09, implying an implied upside of 80.00% versus the current C$0.05. Forecasts are model-based projections and not guarantees. Use position sizing, confirm catalysts from filings, and monitor sector moves in Healthcare for confirmation before scaling exposure. For live quotes and filings, check the company website and profile pages for updates.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.